Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Drug save search
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB®
Published: 2024-03-18 (Crawled : 14:00) - biospace.com/
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review canada submission
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB® Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB® for Acute Treatment of Migraine With or Without Aura in Canada
Published: 2024-03-18 (Crawled : 13:00) - globenewswire.com
SCLX | $0.8407 -13.92% -16.18% 1.7M
|
|
| O: -0.73%
H: 3.31%
C: 0.74%
elyxyb drug patent company health approval review treatment canada migraine submission
Journey Medical Corporation Announces U.S. FDA Acceptance of New Drug Application for DFD-29 for the Treatment of Rosacea
Published: 2024-03-18 (Crawled : 12:30) - globenewswire.com
DERM | $3.425 -3.25% -3.36% 60K
|
|
| O: 2.94%
H: 14.57%
C: 6.86%
FBIO | $1.785 -1.38% -1.4% 120K
|
Health Technology
|
| O: 3.36%
H: 0.5%
C: -4.0%
dfd-29 fda drug corporation treatment medical application
FDA Adcomm Backs Geron’s Anemia Drug for Blood Cancer
Published: 2024-03-15 (Crawled : 12:30) - biospace.com/
GERN | $3.57 2.0% 1.96% 6.6M
|
Health Technology
|
| O: 71.43%
H: 16.33%
C: 12.0%
fda drug anemia cancer blood
BRIGHT GREEN ANNOUNCES ITS EXPANSION CONTINUATION WITH A $100 MILLION SOLAR POWERED GENERATION FIELD TO SUPPLY HEAT AND ELECTRICITY TO ITS DRUG PRODUCTION AND MANUFACTURING FACILITY.
Published: 2024-03-14 (Crawled : 13:00) - globenewswire.com
BGXX | $0.2 1.16% 1.15% 170K
|
|
| O: 6.76%
H: 6.47%
C: -10.23%
drug continuation million solar expansion
Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
PLUR | $5.0 0.2% 12K
|
Manufacturing
|
| O: 0.55%
H: 0.95%
C: -3.09%
drug cell
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | $2.065 -4.4% -4.6% 350K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -4.14%
fda drug granted treatment designation therapeutics
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2024-03-13 (Crawled : 11:00) - globenewswire.com
PEPG | $11.7 -0.17% -0.17% 20K
|
|
| O: 1.94%
H: 4.94%
C: -2.9%
edo51 fda rare drug disease treatment duchenne
Global Irritable Bowel Disease (IBD) Market Research Report 2024: Corticosteroids, JAK inhibitors, TNF inhibitors, Other Drug Classes Insights and Forecast 2019-2029
Published: 2024-03-13 (Crawled : 03:00) - prnewswire.com
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.66%
H: 0.0%
C: 0.0%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.27%
H: 0.5%
C: 0.11%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.59%
H: 0.01%
C: -1.45%
drug disease report research global market
Global Immune Thrombocytopenia Drug Markets, 2019-2022 and 2023-2029: Advanced Drug Delivery Technologies Transform Management, Second-Generation TPO-RAs Revolutionize Treatment Options
Published: 2024-03-12 (Crawled : 00:00) - prnewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -0.04%
H: 0.0%
C: 0.0%
drug treatment global advanced
BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
Published: 2024-03-12 (Crawled : 15:00) - globenewswire.com
BGXX | $0.2 1.16% 1.15% 170K
|
|
| O: -0.14%
H: 158.62%
C: 45.93%
drug million expansion
Everest Medicines' Partner Calliditas Therapeutics Announces U.S. FDA Grants an Additional Seven-Year Orphan Drug Exclusivity Period for Nefecon®
Published: 2024-03-12 (Crawled : 02:00) - prnewswire.com
CALT | $18.5 1.65% 1.62% 1.5K
|
Health Technology
|
| O: 1.48%
H: 0.44%
C: -2.26%
nefecon fda drug grants therapeutics
FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug ...
Published: 2024-03-11 (Crawled : 17:00) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.0%
H: 2.38%
C: 1.12%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
fda drug wegovy approved
FDA Decisions: Wegovy Approved for CV Indication; Viatris and Mapi’s MS Drug Rejected
Published: 2024-03-11 (Crawled : 14:30) - biospace.com/
PRGO | $31.23 2.43% 0.0% 960K
|
Health Technology
|
| O: 0.0%
H: 2.38%
C: 1.12%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: 0.43%
H: 0.0%
C: 0.0%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.26%
H: 0.0%
C: 0.0%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.57%
H: 0.0%
C: 0.0%
fda drug wegovy approved
FDA Grants Orphan Drug and Pediatric Exclusivities for CRESEMBA® (isavuconazonium sulfate) for Invasive Aspergillosis and Invasive Mucormycosis in Children
Published: 2024-03-11 (Crawled : 13:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.41%
H: 5.06%
C: 4.01%
cresemba fda drug children grants
Nurix Therapeutics Announces U.S. FDA Lifts Partial Clinical Hold on NX-2127 Phase 1 TrialNurix cleared to introduce new chirally controlled NX-2127 drug product and resume enrollment of new patients into the study
Published: 2024-03-11 (Crawled : 12:30) - biospace.com/
NRIX 6 d | $13.73 -2.83% -2.91% 520K
|
Health Technology
|
| O: 1.14%
H: 4.19%
C: -5.93%
nx-2127 fda cleared drug therapeutics study
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
Published: 2024-03-11 (Crawled : 11:00) - globenewswire.com
TVTX | $5.46 -4.88% -5.13% 2M
|
Health Technology
|
| O: -0.81%
H: 1.51%
C: -6.98%
filspari nephropathy drug approval food treatment application therapeutics
Everest Medicines Announces Acceptance of VELSIPITY® New Drug Application in Macau
Published: 2024-03-11 (Crawled : 01:00) - prnewswire.com
KZR | $0.8016 -2.95% -3.04% 420K
|
Health Technology
|
| O: 0.01%
H: 1.22%
C: -0.28%
velsipity drug application
United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Published: 2024-03-10 (Crawled : 00:00) - globenewswire.com
MESO | $6.21 3.5% 3.38% 200K
|
Health Technology
|
| O: 16.28%
H: 27.6%
C: 6.4%
drug device approval food heart
Biden Turns Up Heat on Big Pharma’s Drug Prices in State of the Union Address
Published: 2024-03-08 (Crawled : 18:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
drug state
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.